SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors
CHICAGO, Feb. 24, 2022 /PRNewswire/ -- SIWA THERAPEUTICS, INC, which has developed SIWA318H, a proprietary monoclonal antibody that has caused complete remission of pancreatic cancer in vivo in humanized mice, announced today that it has appointed Deborah Wince-Smith to its Board of Directors, effective February 22, 2022.Ms. Wince-Smith is the President and CEO of the Council on Competitiveness, a coalition of CEOs, university presidents, labor leaders and national laboratory directors, committed to driving U.S. competitiveness. She has more than 20 years of experience as a senior U.S. government official, as the first Senate-confirmed Assistant Secretary for Technology Policy in the U.S. Department of Commerce in the Administration of President George H.W. Bush, and as the Assistant Director for International Affairs in the White House Office of Science and Technology Policy in the Reagan Administration. She served as…